联康生物科技集团(00690)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00690 联康生物科技集团

已收盘 08-24 13:47:36

0.061

+0.000

0.00%

最高0.061	最低0.059	成交量4.00万
今开0.059	昨收0.061	日振幅3.28%
总市值3.64亿	流通市值3.64亿	总股本59.71亿
成交额2,400	换手率0.00%	流通股本59.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00690","market":"HK","secType":"STK","nameCN":"联康生物科技集团","latestPrice":0.061,"timestamp":1787550456989,"preClose":0.061,"halted":0,"volume":40000,"delay":0,"changeRate":0,"floatShares":5971000000,"shares":5971000000,"eps":0.0156,"marketStatus":"已收盘","change":0,"latestTime":"08-24 13:47:36","open":0.059,"high":0.061,"low":0.059,"amount":2400,"amplitude":0.032787,"askPrice":0.061,"askSize":80000,"bidPrice":0.057,"bidSize":1000000,"shortable":0,"etf":0,"ttmEps":0.015629,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787621400000},"marketStatusCode":5,"adr":0,"listingDate":1005494400000,"exchange":"SEHK","adjPreClose":0.061,"dividendRate":0.04541,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":0.00587,"lotSize":20000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00690","defaultTab":"news","newsList":[{"id":"1131936074","title":"联康生物科技集团(00690)特别股东大会通过向四名高管授予购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1131936074","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131936074?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:41","pubTimestamp":1787132485,"startTime":"0","endTime":"0","summary":"8月19日，联康生物科技集团有限公司公布，于2026年8月19日举行的股东特别大会已按投票表决方式通过全部四项普通决议案，同意根据购股权计划向四名核心管理层合共授出300,000,000份购股权。公告显示，截至会议当日，公司已发行股份总数为5,971,228,147股，公司没有持有库藏股份，亦无待注销的已购回股份。本次购股权授予方案获通过后，公司将按购股权计划相关条款推进后续工作。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168307366","title":"联康生物科技集团（00690）将于8月26日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1168307366","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168307366?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:15","pubTimestamp":1786698957,"startTime":"0","endTime":"0","summary":"联康生物科技集团有限公司（00690）8月14日公告，公司董事会已定于2026年8月26日（星期三）在其注册办事处召开会议，审议并批准集团及其附属公司截至2026年6月30日止六个月的中期财务业绩及其发布事宜。\n公告显示，董事会目前由四名执行董事梁国龙先生（主席）、陈大伟先生（副主席）、赵志刚先生（行政总裁）及闻亚磊博士（首席营运官）；两名非执行董事邱国荣先生、张清女士；以及三名独立非执行董事周启明先生、任启民先生、马青山先生组成。\n公司强调，交易所及联交所对本公告内容概不负责，对其准确性或完整性亦不发表任何声明，并明确表示概不就因倚赖该等内容而引致之任何损失承担责任。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616477","title":"联康生物科技集团(00690)发盈警 预计上半年净溢利减少至约3000万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616477","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616477?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:57","pubTimestamp":1786093023,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联康生物科技集团 发布公告，预期截至2026年6月30日止六个月集团取得净溢利约为3000万港元，而截至2025年6月30日止六个月，集团取得净溢利约为7596万港元。二是部分集采中选药品会按照新的中标价格销售。截止到2026年6月30日，集团财务状况与现金流非常稳定，足以支撑公司各项业务的需求，现金及现金等价物不低于1.40亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169037035","title":"联康生物科技集团（00690）发盈警：2026财年中期净利预降至约30百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169037035","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169037035?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:56","pubTimestamp":1786092963,"startTime":"0","endTime":"0","summary":"2026年8月7日，联康生物科技集团有限公司发布盈利预警称，根据对截至2026年6月30日止六个月未經審核綜合管理賬目的初步評估，预计期内将录得净溢利约30百万元港元，较2025年同期的75.96百万元港元下降约45.96百万元，降幅约60.6%。联康生物科技集团提醒投资者，以上数据基于初步评估，未经核数师审阅，实际业绩或有差异。公司计划于2026年8月26日公布截至2026年6月30日止六个月的中期业绩。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125445260","title":"联康生物科技集团更新2026年7月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1125445260","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125445260?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:20","pubTimestamp":1785748828,"startTime":"0","endTime":"0","summary":"联康生物科技集团有限公司于2026年8月3日发布截至2026年7月31日的月度报告。公告显示，公司法定股本及已发行股份在报告期内保持稳定，未出现新增股份发行、回购或注销。公司信息显示，联康生物科技集团的法定及注册股本维持在500,000,000,000股，面值每股0.01港元，对应注册股本总额5,000,000,000港元。报告期末，公司已发行股份合计5,971,228,147股，较上月底并未发生增减变化。报告期内未见行权、授出或失效情况，亦无因行权导致的股份增发或库藏股转让。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121805620","title":"联康生物科技集团（00690）拟于8月19日召开股东特别大会　审议向四名高管授出合计3亿份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1121805620","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121805620?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:31","pubTimestamp":1785317492,"startTime":"0","endTime":"0","summary":"联康生物科技集团7月30日发布公告，公司将于2026年8月19日10时30分在香港新界沙田香港科学园科技大道东20号5楼502室召开股东特别大会，审议四项普通决议案，内容均涉及根据2026年5月26日已获股东特别大会批准并采纳的购股权计划，向公司主要管理层成员授出购股权。上述四项购股权总数合计300,000,000份，全部须经即将举行的股东特别大会以普通决议案形式表决通过后方可生效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158657996","title":"联康生物更新6月股份变动月报表，授出300,000,000份新期权","url":"https://stock-news.laohu8.com/highlight/detail?id=1158657996","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158657996?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:45","pubTimestamp":1783327538,"startTime":"0","endTime":"0","summary":"联康生物科技集团有限公司于2026年7月6日发布2026年6月的证券变动月报表，报告期为2026年6月1日至6月30日。公告显示，公司注册股本及已发行股份数量保持不变，期末普通股已发行股份总数仍为5,971,228,147股。本月公司注册股本维持在500,000,000,000股，面值每股港币0.01元，法定股本总额港币5,000,000,000元，未发生增减变动。期权与激励计划方面，2026年股份期权计划本月授出300,000,000份新期权，行使价为每股港币0.09元。截至6月末，各期权合计对应的潜在发行股份数量相应增加。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648631566","title":"小鹏集团与神州租车达成全场景合作，批量交付1300台新能源车","url":"https://stock-news.laohu8.com/highlight/detail?id=2648631566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648631566?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:01","pubTimestamp":1783076507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00690","09868","XPEG","BK4551","XPEV","BK1161","BK4555","BK4526","BK4505","BK4099","EVS.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645819312","title":"联康生物科技集团(00690)授出3亿份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2645819312","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645819312?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:12","pubTimestamp":1782310334,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联康生物科技集团(00690)发布公告，公司于2026年6月24日已根据购股权计划向四名合资格参与者(须待彼等接纳)授出购股权，以认购合共3亿股股份(于悉数行使后及可按购股权计划予以调整)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645319819","title":"联康生物科技集团(00690.HK)授出3亿份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2645319819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645319819?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:12","pubTimestamp":1782310334,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142183940","title":"联康生物科技集团更新5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1142183940","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142183940?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:01","pubTimestamp":1780477302,"startTime":"0","endTime":"0","summary":"联康生物科技集团有限公司（股票代码：00690）于2026年6月3日披露2026年5月股份变动月报表。报告期内，公司法定注册股本维持在500,000,000,000股普通股，面值每股港币0.01，合计港币50亿元。公司已发行普通股5,971,228,147股，与上月底持平，库藏股数目保持为零。\n公司现有2016年股份期权计划合计420,589,000份股份期权，本月并无行权或转让交易，期权数量及股本结构保持稳定。截至2026年5月底，公司已满足香港联交所上市规则的公众持股量要求，所有相关发行与处置均遵守适用的法律法规。\n该公告由公司秘书何咏欣女士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196899537","title":"联康生物科技集团2026年4月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1196899537","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196899537?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:21","pubTimestamp":1777886474,"startTime":"0","endTime":"0","summary":"联康生物科技集团有限公司于2026年5月4日发布2026年4月证券变动月报表。公告显示，公司本月已发行股份数量为5,971,228,147股，库藏股份数量为0股，与上月末保持一致。另据公告披露，联康生物科技集团于报告期内共拥有9批次2016年股份期权计划，对应期权数量合计420,589,000股。截至4月底，相关股份期权数量及其行使情况均未发生变化，本月无新增股份发行或期权行权记录。据悉，本次公告由公司秘书何詠欣女士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629839787","title":"联康生物科技集团(00690)建议终止现有购股权计划及采纳新购股权计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2629839787","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2629839787?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:15","pubTimestamp":1776946548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联康生物科技集团(00690)发布公告，董事会已建议(i)终止现有购股权计划;及(ii)采纳新购股权计划，以供股东批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183742344","title":"联康生物科技集团拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1183742344","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183742344?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:47","pubTimestamp":1776854850,"startTime":"0","endTime":"0","summary":"联康生物科技集团有限公司于香港联合交易所有限公司主板上市。根据最新公告，董事会建议寻求股东批准一项股份购回授权，最多回购相当于公司于相关决议案获股东大会通过当日已发行股份总数10%的股份。公告显示，截至决议案通过当日，公司已发行股份数约为5,971,228,147股，代表最多可回购约597,122,814股。根据公告提供的最近月份股价区间，联康生物科技集团股价曾在0.055港元至0.168港元之间波动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联康生物科技集团拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135819601","title":"联康生物科技集团2025年收入5.86亿元 净利同比增长12.7% 聚焦创新研发与国际化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1135819601","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135819601?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:43","pubTimestamp":1776854621,"startTime":"0","endTime":"0","summary":"联康生物科技集团在截至2025年12月31日止年度实现收入5.86亿元，同比增长约6%。毛利为4.88亿元，毛利率约83%，与上年度水平基本持平。年度溢利达到0.93亿元，同比上升12.7%。除税前溢利约为1.02亿元，较上一年度的0.91亿元增长11.4%。此外，集团于报告期内的研发开支为0.40亿元，较上年度有所回落。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联康生物科技集团2025年收入5.86亿元 净利同比增长12.7% 聚焦创新研发与国际化布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133486624","title":"联康生物科技集团3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1133486624","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133486624?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:42","pubTimestamp":1775637745,"startTime":"0","endTime":"0","summary":"联康生物科技集团有限公司（股票代码：00690）在2026年4月8日发布截至2026年3月31日的股份变动月报表。报告显示，公司本月内未有新增发行、库藏或注销股份活动，已发行普通股数依旧维持在5,971,228,147股，库存股份数为0股。\n根据公告，公司法定股本保持在500,000,000,000股，每股面值港币0.01元，总额为港币50亿。期权方面，多个先前授予的期权累计数量合计仍保持不变，报告期间未有期权行使或失效记录。\n公司强调，截至本月底已符合相关公众持股量要求，并确认遵守香港联交所《上市规则》及其他适用法律法规规定。公告由公司秘书何咏欣女士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624703525","title":"联康生物科技集团(00690)：股东股权框架变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2624703525","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624703525?lang=zh_cn&edition=full","pubTime":"2026-04-02 18:08","pubTimestamp":1775124483,"startTime":"0","endTime":"0","summary":"联康生物科技集团(00690)发布公告，公司董事会获梁国龙先生(执行董事兼董事会主席)(梁先生)及其若干受控法团告知，由于梁先生及其家族成员组成的梁氏家族的家族安排，故有关股权发生变动(股权变动)。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_2.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_2.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00690","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622790858","title":"联康生物科技集团(00690)发布年度业绩 年内溢利9332.7万港元 同比增加12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622790858","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2622790858?lang=zh_cn&edition=full","pubTime":"2026-03-28 00:43","pubTimestamp":1774629796,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联康生物科技集团(00690)发布截至2025年12月31日止年度业绩，该集团期内取得收益5.86亿港元，同比增加6%;年内溢利9332.7万港元，同比增加12.7%;每股基本盈利1.56港仙。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联康生物科技集团(00690)发布年度业绩 年内溢利9332.7万港元 同比增加12.7%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124133894","title":"联康生物科技集团将于2026年6月12日派发末期股息每股0.00313元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124133894","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124133894?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:04","pubTimestamp":1774623869,"startTime":"0","endTime":"0","summary":"联康生物科技集团(00690)宣布，截至2025年12月31日止年度末期股息每股0.00313港元，股息尚待于2026年5月26日股东大会上批准。除净日为2026年5月28日，有意参与股息分派的股东须在2026年5月29日16时30分前递交股份过户登记文件。公司将于2026年6月1日至6月3日暂停办理股份过户登记，6月3日为记录日期，股息预计于2026年6月12日派发。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00690"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620563415","title":"联康生物科技集团(00690)股东将股票存入香港上海汇丰银行 存仓市值8715.96万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620563415","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2620563415?lang=zh_cn&edition=full","pubTime":"2026-03-17 08:11","pubTimestamp":1773706266,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，3月16日，联康生物科技集团(00690)股东将股票存入香港上海汇丰银行，存仓市值8715.96万港元，占比13.64%。联康生物科技集团2025年中期业绩显示，收益3.10亿港元，同比增长13.4%;净利润7595.5万港元，同比增长12.7%;每股基本盈利1.27港仙。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0540923850.HKD","LU1481107354.HKD","HSHD.SI","LU0149721374.USD","LU0516422952.EUR","BK1601","03143","LU0310800965.SGD","BK4585","LU0417516738.SGD","LU2449936058.SGD","BK4588","LU0164880469.USD","BK1231","LU0634319403.HKD","LU0128525689.USD","HSBA.UK","LU0348735423.USD","00690","LU0052756011.USD","LU0516423174.USD","BK4207","LU2236285917.USD","LU0516422366.SGD","LU0516423091.SGD","LU1267930227.SGD","00005","HSBH","LU0516422440.USD","BK1572","HSBC","IE0008369823.USD","BK1161","BK1610","BK4521"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uni-bioscience.com","stockEarnings":[{"period":"1week","weight":0.1091},{"period":"1month","weight":-0.2738},{"period":"3month","weight":-0.2738},{"period":"6month","weight":-0.4455},{"period":"1year","weight":-0.6039},{"period":"ytd","weight":-0.4505}],"compareEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":0.0449},{"period":"3month","weight":0.0158},{"period":"6month","weight":-0.0153},{"period":"1year","weight":0.036},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联康生物科技集团有限公司是一家主要从事医药产品制造及销售业务的香港投资控股公司。该公司通过四大分部运营。自制化学药品分部从事自制化学药品的制造及销售业务。其化学药品包括匹纳普等。自制生物药品分部从事自制生物药品的制造及销售。其生物药品包括金因肽及金因舒等。自制生物在研产品分部从事自制生物在研产品的规模化生产业务。其生物在研产品包括Uni-E4及Uni-PTH等。第三方药品分部从事第三方药品销售业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.409091,"avgChangeRate":0.002538},{"month":2,"riseRate":0.521739,"avgChangeRate":0.059118},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.009095},{"month":4,"riseRate":0.47619,"avgChangeRate":0.112051},{"month":5,"riseRate":0.47619,"avgChangeRate":0.046594},{"month":6,"riseRate":0.454545,"avgChangeRate":0.055275},{"month":7,"riseRate":0.5,"avgChangeRate":0.009245},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.028865},{"month":9,"riseRate":0.380952,"avgChangeRate":0.495714},{"month":10,"riseRate":0.238095,"avgChangeRate":-0.045656},{"month":11,"riseRate":0.47619,"avgChangeRate":-0.021376},{"month":12,"riseRate":0.318182,"avgChangeRate":-0.003974}],"exchange":"SEHK","name":"联康生物科技集团","nameEN":"UNI-BIO GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联康生物科技集团(00690)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联康生物科技集团(00690)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联康生物科技集团,00690,联康生物科技集团股票,联康生物科技集团股票老虎,联康生物科技集团股票老虎国际,联康生物科技集团行情,联康生物科技集团股票行情,联康生物科技集团股价,联康生物科技集团股市,联康生物科技集团股票价格,联康生物科技集团股票交易,联康生物科技集团股票购买,联康生物科技集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联康生物科技集团(00690)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联康生物科技集团(00690)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}